Few U.S. industries glow more warmly with health and confidence than the U.S. ethical drug industry, which has more than doubled its business since World War II. This week, as the American Pharmaceutical Manufacturers Association held its midwinter meeting in Manhattan, its 214 members, representing virtually every leading ethical drug house, had added reason for feeling robust. The industry is about to close its books on a record year, stands to run up sales of $1.7 billion and reap profits 15%-20% above 1956. Said Association President Francis C. Brown, president of Schering...
To continue reading:
or
Log-In